Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

LUNG

Pulmonx Corp

Dec 13 • 04:00PM ET

6.10

Dollar change +0.05
Percentage change 0.83	%

Healthcare • Medical Devices • USA • NASD

Peers: DHR MDT EW ISRG SYK BSX ZBH HOLX XRAY ALGN

| Held by: VTI IWM VXF IWO SCHA VTWO VHT DFAS IWC ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.47	Insider Own	9.29%	Shs Outstand	39.49M	Perf Week	-4.69%
Market Cap	242.87M	Forward P/E	-	EPS next Y	-1.60	Insider Trans	-1.78%	Shs Float	35.82M	Perf Month	-9.23%
Income	-57.11M	PEG	-	EPS next Q	-0.44	Inst Own	90.22%	Short Float	2.28%	Perf Quarter	-25.15%
Sales	79.30M	P/S	3.06	EPS this Y	2.61%	Inst Trans	2.23%	Short Ratio	3.70	Perf Half Y	5.72%
Book/sh	2.38	P/B	2.56	EPS next Y	-2.49%	ROA	-32.41%	Short Interest	0.82M	Perf Year	-51.59%
Cash/sh	2.71	P/C	2.25	EPS next 5Y	20.10%	ROE	-51.99%	52W Range	5.46 - 14.84	Perf YTD	-52.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-25.16%	ROI	-38.33%	52W High	-58.88%	Beta	0.70
Dividend TTM	-	Quick Ratio	6.77	Sales past 5Y	30.02%	Gross Margin	73.91%	52W Low	11.72%	ATR (14)	0.44
Dividend Ex-Date	-	Current Ratio	7.70	EPS Y/Y TTM	9.36%	Oper. Margin	-71.23%	RSI (14)	42.44	Volatility	6.83% 7.05%
Employees	279	Debt/Eq	0.59	Sales Y/Y TTM	22.34%	Profit Margin	-72.01%	Recom	1.67	Target Price	11.58
Option/Short	Yes / Yes	LT Debt/Eq	0.59	EPS Q/Q	7.88%	Payout	-	Rel Volume	1.90	Prev Close	6.05
Sales Surprise	0.49%	EPS Surprise	19.73%	Sales Q/Q	15.39%	Earnings	Oct 30 AMC	Avg Volume	220.16K	Price	6.10
SMA20	-4.24%	SMA50	-7.34%	SMA200	-17.56%	Trades		Volume	418,401	Change	0.83%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-24	Downgrade	Citigroup	Buy → Neutral	$17 → $7.50
Jun-04-24	Initiated	Lake Street	Buy	$12
Feb-23-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$16 → $14
Sep-05-23	Initiated	Craig Hallum	Buy	$18
Feb-27-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$10 → $15
Jan-03-23	Downgrade	BofA Securities	Neutral → Underperform	$8
Dec-12-22	Upgrade	Citigroup	Neutral → Buy	$14 → $10
Jul-11-22	Downgrade	Citigroup	Buy → Neutral	$23 → $19
Mar-02-22	Resumed	BofA Securities	Neutral	$28
Dec-08-21	Upgrade	Piper Sandler	Neutral → Overweight	$45
Apr-01-21	Initiated	Citigroup	Buy	$60
Mar-25-21	Initiated	Piper Sandler	Neutral	$50
Mar-10-21	Upgrade	BofA Securities	Neutral → Buy	$72
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral
Oct-26-20	Initiated	Wells Fargo	Equal Weight	$46
Oct-26-20	Initiated	Stifel	Buy	$50
Oct-26-20	Initiated	Morgan Stanley	Equal-Weight	$44
Oct-26-20	Initiated	Canaccord Genuity	Buy	$49
Oct-26-20	Initiated	BofA Securities	Buy	$50

Show Previous Ratings

Nov-21-24 09:55AM	Does Pulmonx (LUNG) Have the Potential to Rally 117.74% as Wall Street Analysts Expect? (Zacks)
Nov-20-24 04:05PM	Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-19-24 09:00AM	Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers (Business Wire)
Nov-07-24 04:05PM	Pulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire)
Nov-05-24 04:05PM	Pulmonx to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire) +8.44%
09:55AM	Loading…
09:55AM	Wall Street Analysts Predict an 89.61% Upside in Pulmonx (LUNG): Here's What You Should Know (Zacks)
Oct-31-24 07:00AM	Pulmonx Corp (LUNG) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... (GuruFocus.com) -7.95%
Oct-30-24 06:25PM	Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Pulmonx Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-16-24 04:05PM	Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024 (GlobeNewswire) -5.74%
Sep-09-24 04:05PM	Pulmonx Announces Presentation of Clinical Data from the AeriSeal CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024 (GlobeNewswire) +9.00%
Aug-29-24 04:05PM	Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference (GlobeNewswire)
Aug-22-24 04:05PM	Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference (GlobeNewswire) +9.32%
Jul-31-24 05:50PM	Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.08%
04:05PM	Pulmonx Reports Second Quarter 2024 Financial Results (GlobeNewswire)
04:05PM	Loading…
Jul-29-24 04:05PM	Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire) -9.16%
Jul-10-24 04:05PM	Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024 (GlobeNewswire) +13.86%
May-22-24 09:55AM	How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3% (Zacks)
May-06-24 05:03PM	Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.50%
09:55AM	Wall Street Analysts See a 56.11% Upside in Pulmonx (LUNG): Can the Stock Really Move This High? (Zacks)
May-03-24 09:43AM	Pulmonx Corporation (NASDAQ:LUNG) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +21.50%
07:05AM	Q1 2024 Pulmonx Corp Earnings Call (Thomson Reuters StreetEvents)
03:38AM	Pulmonx Corp (LUNG) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Improved ... (GuruFocus.com)
May-01-24 08:55PM	LUNG Stock Earnings: Pulmonx Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:05PM	Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:46PM	Pulmonx Corp (LUNG) Q1 2024 Earnings: Surpasses Revenue Estimates Amidst Continued Losses (GuruFocus.com)
04:05PM	Pulmonx Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-10-24 04:05PM	Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024 (GlobeNewswire)
Apr-02-24 04:05PM	Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer (GlobeNewswire) -6.79% -6.58%
05:00PM	Loading…
Mar-15-24 05:00PM	Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-29-24 11:35PM	Steven Cohen's Point72 Asset Management Bolsters Position in Pulmonx Corp (GuruFocus.com)
Feb-26-24 08:00AM	Pulmonx Announces Treatment of the First Patient with the AeriSeal System in CONVERT II Pivotal Trial (Business Wire)
Feb-22-24 09:55AM	Pulmonx Corporation (NASDAQ:LUNG) Q4 2023 Earnings Call Transcript (Insider Monkey) -18.21%
06:56AM	Q4 2023 Pulmonx Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-21-24 04:44PM	Pulmonx Corp (LUNG) Reports Solid Revenue Growth Amidst Increased Operating Expenses (GuruFocus.com)
04:06PM	Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
04:05PM	Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer (GlobeNewswire)
Feb-17-24 12:08AM	Insider Sell: President and CEO French Glendon E. III Sells 20,000 Shares of Pulmonx Corp (LUNG) (GuruFocus.com)
Feb-13-24 01:08PM	PRIMECAP Management Bolsters Position in Pulmonx Corp (GuruFocus.com)
Feb-07-24 04:05PM	Pulmonx to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024 (GlobeNewswire)
Dec-22-23 11:19PM	Insider Sell: President and CEO French Glendon E. III Sells 10,000 Shares of Pulmonx Corp (LUNG) (GuruFocus.com)
Dec-11-23 09:00AM	The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors (GlobeNewswire)
Nov-17-23 01:08PM	Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare (InvestorPlace)
Nov-15-23 04:05PM	Pulmonx to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Oct-31-23 04:05PM	Pulmonx to Participate at Upcoming Investor Conferences (GlobeNewswire) +11.41%
09:00AM	Pulmonx Corporation (NASDAQ:LUNG) Q3 2023 Earnings Call Transcript (Insider Monkey)
07:03AM	Q3 2023 Pulmonx Corp Earnings Call (Thomson Reuters StreetEvents)
Oct-30-23 06:30PM	Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
05:53PM	Pulmonx Corp (LUNG) Reports Record Q3 2023 Financial Results (GuruFocus.com)
04:05PM	Pulmonx Reports Record Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-16-23 04:05PM	Pulmonx to Report Third Quarter 2023 Financial Results on October 30, 2023 (GlobeNewswire)
Oct-10-23 04:05PM	Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue (GlobeNewswire) -13.36%
Aug-30-23 04:05PM	Pulmonx to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-02-23 05:55PM	Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Pulmonx Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-26-23 04:05PM	Pulmonx to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire) +7.23%
Jul-19-23 04:05PM	Pulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023 (GlobeNewswire)
Jul-17-23 08:00AM	Pulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023 (GlobeNewswire)
Jul-10-23 08:47AM	Shareholders in Pulmonx (NASDAQ:LUNG) are in the red if they invested a year ago (Simply Wall St.)
May-03-23 10:43AM	Q1 2023 Pulmonx Corp Earnings Call (Thomson Reuters StreetEvents) +8.63%
May-02-23 05:35PM	Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.90%
04:05PM	Pulmonx Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 08:24PM	7 Nasdaq Small-Cap Stocks Set to Outperform in 2023 (InvestorPlace)
Apr-25-23 04:05PM	Pulmonx to Present at the Bank of America Securities 2023 Health Care Conference (GlobeNewswire) -5.57%
Apr-18-23 04:05PM	Pulmonx to Report First Quarter 2023 Financial Results on May 2, 2023 (Business Wire)
Apr-17-23 02:20PM	Pulmonx Corporation (NASDAQ:LUNG) Not Flying Under The Radar (Simply Wall St.) +6.06%
Feb-24-23 04:00PM	Why Shares of Pulmonx Rose This Week (Motley Fool) +5.98%
Feb-22-23 05:55PM	Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +20.21%
04:05PM	Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-16-23 04:05PM	Pulmonx to Present at the Citi 2023 Healthcare Conference (GlobeNewswire)
Feb-08-23 04:05PM	Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023 (GlobeNewswire)
Jan-31-23 06:57AM	Pulmonx (NASDAQ:LUNG) investors are sitting on a loss of 66% if they invested a year ago (Simply Wall St.)
Dec-14-22 04:05PM	American Lung Association Campaign Shines Spotlight on Endobronchial Valves for Advanced COPD/Emphysema (Business Wire)
Nov-30-22 07:00AM	Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema (Business Wire) +12.73%
Nov-16-22 04:05PM	Pulmonx to Present at the 34th Annual Piper Sandler Healthcare Conference (GlobeNewswire) -8.61%
Nov-11-22 05:12AM	Pulmonx Corporation (NASDAQ:LUNG) Analysts Just Slashed Next Year's Revenue Estimates By 21% (Simply Wall St.) +14.36%
Nov-09-22 06:27AM	Pulmonx Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.) -7.16%
Nov-04-22 12:34PM	Why Pulmonx Stock Is Crashing Today (Motley Fool) -60.94%
08:00AM	Pulmonx to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-03-22 06:45PM	Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -9.53%
04:05PM	Pulmonx Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-27-22 10:02AM	Earnings Preview: Pulmonx Corporation (LUNG) Q3 Earnings Expected to Decline (Zacks) -5.15%
Oct-20-22 04:05PM	Pulmonx to Report Third Quarter 2022 Financial Results on November 3, 2022 (GlobeNewswire)
Oct-14-22 10:01AM	3 Medical Info System Stocks to Gain on Rising Demand for Digital Health (Zacks)
Oct-13-22 09:35AM	Down 27.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Pulmonx Corporation (LUNG) (Zacks)
Sep-09-22 03:29PM	ADDING and REPLACING CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema (Business Wire)
Aug-24-22 04:05PM	Pulmonx to Present at Upcoming September Investor Conferences (Business Wire)
Aug-03-22 09:55AM	Wall Street Analysts Predict a 79% Upside in Pulmonx Corporation (LUNG): Here's What You Should Know (Zacks)
Aug-02-22 11:00PM	Pulmonx Corporation (LUNG) Q2 2022 Earnings Call Transcript (Motley Fool) +5.60%
05:35PM	Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Pulmonx Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-27-22 04:05PM	Pulmonx to Present at the Canaccord Genuity 42nd Annual Growth Conference (Business Wire)
Jul-19-22 04:05PM	Pulmonx to Report Second Quarter 2022 Financial Results on August 2, 2022 (Business Wire)
Jul-18-22 09:55AM	Can Pulmonx Corporation (LUNG) Climb 117% to Reach the Level Wall Street Analysts Expect? (Zacks)
05:15AM	Analysts Just Trimmed Their Price Targets of These 10 Stocks (Insider Monkey)
Jul-06-22 08:10AM	Privia Health (PRVA) Moves 7.4% Higher: Will This Strength Last? (Zacks)
Jun-26-22 08:36AM	Pulmonx (NASDAQ:LUNG) shareholders are up 11% this past week, but still in the red over the last year (Simply Wall St.)
May-03-22 10:00PM	Pulmonx Corporation (LUNG) Q1 2022 Earnings Call Transcript (Motley Fool)
05:35PM	Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates (Zacks)

Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. It operates through the United States, Europe, Middle East, Africa, Asia Pacific, and Other International segments. The company was founded by Rodney Perkins on December 26, 1995 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rose Geoffrey Beran	CHIEF COMMERCIAL OFFICER	Dec 02 '24	Sale	6.18	4,376	27,065	291,057	Dec 04 06:18 PM
Lehman David Aaron	GENERAL COUNSEL	Dec 02 '24	Sale	6.19	5,497	34,006	197,851	Dec 04 06:16 PM
French Glendon E. III	Director	Nov 22 '24	Sale	6.63	20,000	132,600	1,071,974	Nov 26 06:33 PM
GLENDON FRENCH	Officer	Nov 22 '24	Proposed Sale	6.42	20,000	128,400		Nov 22 04:28 PM
French Glendon E. III	Director	Oct 17 '24	Sale	6.52	20,000	130,400	1,091,974	Oct 21 05:45 PM
GLENDON FRENCH	Officer	Oct 17 '24	Proposed Sale	6.80	20,000	136,000		Oct 17 04:20 PM
French Glendon E. III	Director	Sep 12 '24	Sale	8.09	20,000	161,800	1,111,974	Sep 18 06:08 PM
GLENDON FRENCH	Director	Sep 12 '24	Proposed Sale	7.75	20,000	155,000		Sep 12 04:32 PM
Rose Geoffrey Beran	CHIEF COMMERCIAL OFFICER	Sep 03 '24	Sale	6.70	4,586	30,721	295,433	Sep 05 06:10 PM
Lehman David Aaron	GENERAL COUNSEL	Sep 03 '24	Sale	6.69	5,765	38,576	203,348	Sep 05 06:08 PM
Williamson Steven S.	PRESIDENT AND CEO	Aug 20 '24	Buy	6.84	14,245	97,436	219,531	Aug 22 06:41 PM
Rose Geoffrey Beran	CHIEF COMMERCIAL OFFICER	Jun 24 '24	Sale	6.16	1,184	7,293	300,019	Jun 26 06:07 PM
Lehman David Aaron	GENERAL COUNSEL	Jun 03 '24	Sale	6.97	5,475	38,161	209,113	Jun 05 05:59 PM
Rose Geoffrey Beran	CHIEF COMMERCIAL OFFICER	Jun 03 '24	Sale	6.97	4,297	29,950	301,203	Jun 05 05:58 PM
Rose Geoffrey Beran	CHIEF COMMERCIAL OFFICER	May 22 '24	Sale	8.71	1,184	10,313	305,500	May 23 06:07 PM
Rose Geoffrey Beran	CHIEF COMMERCIAL OFFICER	Apr 22 '24	Sale	7.49	1,184	8,868	306,684	Apr 24 06:14 PM
Rose Geoffrey Beran	CHIEF COMMERCIAL OFFICER	Mar 22 '24	Sale	9.36	1,184	11,082	307,868	Mar 26 05:53 PM
Rose Geoffrey Beran	CHIEF COMMERCIAL OFFICER	Mar 01 '24	Sale	9.06	3,097	28,059	239,952	Mar 05 06:22 PM
McKune John	INTERIM CFO	Mar 01 '24	Sale	9.06	1,078	9,767	47,410	Mar 05 06:20 PM
Lehman David Aaron	GENERAL COUNSEL	Mar 01 '24	Sale	9.06	4,351	39,420	145,488	Mar 05 06:18 PM
French Glendon E. III	PRESIDENT AND CEO	Mar 01 '24	Sale	9.06	6,954	63,003	1,116,758	Mar 05 06:15 PM
Rose Geoffrey Beran	CHIEF COMMERCIAL OFFICER	Feb 22 '24	Sale	14.20	1,184	16,813	243,049	Feb 26 06:23 PM
French Glendon E. III	PRESIDENT AND CEO	Feb 15 '24	Sale	14.60	20,000	292,000	1,121,344	Feb 16 07:11 PM
Rose Geoffrey Beran	CHIEF COMMERCIAL OFFICER	Jan 22 '24	Sale	13.13	1,184	15,546	244,233	Jan 24 05:41 PM
French Glendon E. III	PRESIDENT AND CEO	Jan 18 '24	Sale	12.77	10,000	127,700	1,141,344	Jan 22 06:05 PM
Rose Geoffrey Beran	Chief Commercial Officer	Dec 22 '23	Sale	12.75	1,184	15,096	245,417	Dec 27 04:19 PM
French Glendon E. III	President and CEO	Dec 21 '23	Sale	12.42	10,000	124,200	1,151,344	Dec 22 06:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LUNG

Pulmonx Corp

Upgrade your FINVIZ experience